LR-HEALTH-&-BEAUTY
7.6.2019 14:22:08 CEST | Business Wire | Press release
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir. Four months after the market launch and a sensational amount of sold 2.6 million* shots, the revolutionary product was awarded the German Brand Award 2019 yesterday. In competition with "Excellent Brands", the Elixir impressed the top-ranking jury in the "Beauty & Care" category as one of the best product brands in the industry. In addition, the Elixir also received the "Special Mention" distinction in the cross-industry category "Product of the Year", which the jury awards for special aspects in branding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005247/en/
Andreas Friesch, CEO of LR Health & Beauty, is very proud of receiving this award. "Being the 'Winner' of the German Brand Award 2019 is a wonderful recognition for a very special product development. With the LR LIFETAKT 5in1 Beauty Elixir, we demonstrate our extensive health and beauty know-how in a single product. It is a reflection of our spectrum of competence and bears - like most of our products - the 'Made in Germany' seal of quality. Furthermore, the award is a motivation to continue developing pioneering innovations in the future as well.”
Excellent Beautyfood: LR LIFETAKT 5in1 Beauty Elixir
The most successful product launch in the history of the company, the LR LIFETAKT 5in1 Beauty Elixir fulfills five beauty wishes at once: youthful appearance, clear skin, firm body, healthy hair and strong nails. With just one shot a day, it ensures radiant beauty from head to toe – thanks to the unique double-complex with the most important active ingredients for beauty from science and from the power of nature. The 5in1 Beauty Elixir distinguishes itself from other beautyfood products on the market with the preventative complex that protects skin from the inside out from environmental factors and prevents the signs of ageing. Moreover, the active complex activates the beauty process in the body, ensuring radiant beauty from head to toe - no matter the age of the person using it. The Elixir has a fruity-fresh taste and is free of sweeteners, artificial colours, lactose and gluten.
The direct sales method with trained, independent sales partners who introduce and sell products in a professional manner with a high consultation level, is crucial to the success of the product.
German Brand Award | German Design Council
The German Brand Award is a prize offered by the German Design Council and the German Brand Institute, crowning the most innovative brands, consistent branding, and sustainable brand communication. It is divided into two competitions: "Excellent Brands" awards the best product and company brands in an industry. "Excellence in Brand Strategy and Creation" honours the strongest campaigns, concepts and strategies in individual disciplines.
The German Design Council is an independent and internationally active institution that assists companies to efficiently communicate design and brand competence, while at the same time aiming to strengthen the general public's understanding of design. Established as a foundation in 1953, at the initiative of the German Bundestag by the Federation of German Industries and several leading companies, the German Design Council supports the advancement of design and branding with its competitions, exhibitions, conferences, seminars and publications. Currently, over 300 companies both inland and abroad belong to the circle of founders of the German Design Council. More information: german-brand-award.com
LR Health & Beauty
With its "More quality for your life" campaign, the LR Group, with headquarters in Ahlen, Westphalia, produces and markets various beauty and health products in 28 countries. The products include care and decorative cosmetics, dietary supplements and perfume. The processing of aloe vera has been one of LR Health & Beauty's key areas of expertise for over 15 years, whereby the precious inside of the leaf is exclusively used. With an annual volume of 12,000 tons of aloe vera leaves, today the company is one of the largest manufacturers of aloe vera products worldwide. With 1,100 employees and thousands of registered Sales Partners and clients, LR is one of the leading direct sales companies in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005247/en/
Contact:
LR Health & Beauty Almut Kellermeyer Head of PR / Public Affairs Tel.: +49 2382 7060-106 E-mail: A.Kellermeyer@LRworld.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom